Dr. Sun has extensive experience of serving executive positions at multiple entrepreneurial biopharmaceutical companies. She is an expert in drug registration, regulatory affairs and senior project management, and had been secretary general of Shanghai Medicine Quality Association Cell Therapy Committee. She has completed more than ten IND and NDA applications for bio/immunotherapy drugs. Dr. Sun had served Fosun Kite biotechnology Co., Ltd and Henlius, and was in charge of the NDA approvals for the first CAR-T product FKC876’s in China, and the first biosimilar drug汉利康® (HLX-01, rituximab injection) in China. 

Dr. Sun Minmin completed her Ph.D. at Fudan University and obtained her Master's degree from Tsinghua University, with a major in pharmacology and a research focus on tumor immunology.

Dr. Jiang serves a SVP of Strategy and Operations and is driving forward the company strategies, fund raising, and business development. Dr. Jiang held a range of leadership roles in bio pharma for more than 10 years, his highest positions included the Deputy General Manager, and Vice-Chairman of the board of directors. His areas of expertise include corporate operations, research management, external financing acquisition, business collaboration, intellectual property (IP) operations and implementation, investor relationship and business development.

Dr. Jiang received his Doctor’s degree in Immunology from Fudan University School of Medicine, and Master of Business Administration from Fudan University.

Mr. Shen has 30 years management experience in bio pharmaceuticals. He was a founding member at Fosun-Kite. His areas of specialties cover immune cell therapy, monoclonal antibodies, cytokines, peptide drugs and vaccines. He has led a broad spectrum of biological drug development from R&D, quality system building, manufacturing, tech transfer, clinical team building, trial applications, clinical samples manufacturing and quality approval, along with the design of the manufacturing plants, validation, drug application and registrations.

Mr. Shen received his M.B.A. from Shanghai Jiaotong University, and his Bachelor's in Biological Science from Ocean University of China.

Dr. Hao serves as Head of R&D center of Immunofoco and is responsible for drug discovery and non-clinical researches. Dr. Hao has an extensive experience in immune cell therapy drug research and development, he held a range of challenging roles in different biotech companies, where he led multiple launches of new CAR-T drugs to treat hema-malignancies and solid tumors, from pre-clinical to the clinical phases. Dr. Hao has more than ten research articles published in scientific journals e.g. Hepatology, JVI etc. He has more than ten patents in China and internationally.

Dr. Hao received his Doctor’s degree in Microbiology from Wuhan University.

Mrs. Wang serves as the co-founder of Immunofoco. With more than 18 years of leadership in human resource and administrative management, she serves as the executive assistant of Chairman of the board and is in charge of financing, and legal affairs. she has served in a complex of organizations including biotech, healthcare big data, and educational firms domestically and aboard, she is an expert in human resource management system set up and operations, talent acquisition and expansion, team structuring and organization.

Mrs. Wang possesses a M.S. degree in Social Psychology from Fudan University.

With nearly 20 years of experience in multinational biopharmaceutical companies working on different modalities such as eye drops, vaccines, monoclonal antibodies, and cell therapy, he has worked at JW Therapeutics, Fosun Kite, Boehringer Ingelheim, Abbott, and Santen Pharmaceutical. He has extensive expertise in GMP facility construction, laboratory setup, quality control system establishment, validation, technology transfer, regulatory submissions, plant operations, and GMP compliance. He has received systematic training in laboratory management and GMP audits in countries such as Japan, US, and Singapore.

Zhou holds a Bachelor's degree in Biotechnology from Soochow University and a Master's in Management from Renmin University of China.

With more than 30 years of financial management experience, Jeff began his career at multinational pharmaceutical leaders including GSK and Sanofi, where he built deep expertise in business-finance integration and strategic financial planning. He later moved into the biotech sector, successfully leading multiple private financing rounds and IPO for companies such as CANbridge and Cellomics, playing an instrumental role in achieving key corporate milestones. Jeff is skilled at aligning financial strategy with biopharmaceutical industry dynamics. Through effective capital management, efficient financial operations, and a strong internal control framework, he delivers reliable support for corporate value creation and sustainable growth.

Jeff holds a Bachelor’s degree in Business Administration and Accounting from the University of Wisconsin-Madison, USA, as well as a Postgraduate Diploma in Public Financing and Capital Market from The University of Hong Kong. He is also a qualified Hong Kong Certified Public Accountant (HKICPA) and a member of the American Institute of CPAs (AICPA).